Celltrion Enters Race For Ocrevus Biosimilar, Files Omalizumab In Europe

Roche’s Ocrevus Brought In Sales Of CHF6bn In 2022, Including CHF4.5bn In US

 
• By Dean Rudge

Celltrion is keeping both eyes firmly on the future as it begins clinical trials for one biosimilar and files another in Europe.

Race (Panther Media GmbH/Alamy Stock Photo)
• Source: Shutterstock (Panther Media GmbH / Alamy Stock/Alamy Stock Photo)

More from Biosimilars

More from Products